Burning Rock Biotech Limited is a precision oncology diagnostics company specializing in next-generation sequencing (NGS)-based cancer therapy selection and early detection. The company operates through a two-pronged commercial infrastructure comprising a central laboratory model and an in-hospital model, serving hospitals and pharmaceutical companies primarily in China and internationally. Its product portfolio includes NGS-based cancer therapy selection tests such as OncoCompass and OncoScreen, minimal residual disease (MRD) testing via CanCatch, and the multi-cancer early detection test OverC. The company provides companion diagnostics and central laboratory services to biopharmaceutical partners, including collaborations with AstraZeneca, Bayer, and Johnson & Johnson. Founded in 2014, Burning Rock Biotech utilizes proprietary technologies for tissue and liquid biopsy sample analysis, supported by internationally accredited laboratories in China and the United States.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Diagnostics & Research Homepage brbiotech.com
Sector Healthcare IR page brbiotech.com/en
Tags
next-generation sequencing, precision oncology, liquid biopsy, tissue biopsy, companion diagnostics, minimal residual disease, early cancer detection, biomarker research, central laboratory services, in-hospital diagnostics, OncoCompass, OncoScreen, CanCatch, OverC, brPROPHET, OncoCompass IO, OncoScreen IO, OncoCompass Target, OncoScreen Plus, OncoCompass Plus, Guangzhou Burning Rock Dx Co. Ltd., Guangzhou Burning Rock Medical Equipment Co. Ltd., Burning Rock (Beijing) Biotechnology Co. Ltd., Beijing Burning Rock Biotech Limited, Guangzhou Burning Rock Biotech Limited, BR Hong Kong Limited
Press page —

Metrics

Valuation  
Market cap $ 185.437M
Market cap (USD) $ 185.437M
P/E -25.19
PEG —
P/BV 2.42
P/S 2.27
P/OCF -2.80
P/FCF -2.47
Dividend yield —
Turnover / mcap —
Returns  
ROE -10.1%
ROI -10.1%
ROIC -7.5%
Profit margin -10.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 2.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 20
Quality score -41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 77.157M 70.667M 75.696M 81.662M 78.503M 62.15M 54.41M
Net profit -7.916M -47.489M -92.07M -140.815M -123.15M -58.873M -24.114M
Free cash flow -4.819M -13.382M -37.167M -75.226M -105.454M -19.348M -38.635M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 20.15 6.75 0.93 2.25 9.53 23.1 —
Price performance 12m 1.99 6.26 -0.59 -0.76 -0.59 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (CNY) — — 88.8M 13.5M 14.5M 15.9M 17.9M 20.8M 24.3M
↳ YoY growth +7.0% +10.2% +12.1% +16.6% +16.5%
↳ 5y CAGR +12.4%
Borrowings, current (CNY) — — 2.37M 1.13M 372,000 0.00 — — —
Borrowings, non-current (CNY) — — 18.3M 0.00 — — — 0.00 243,000
Lease liabilities (CNY) — — — 4.82M 13.2M 7.36M 1.74M 7.17M 5.89M
Cash and deposits (CNY) 54.8M 93.3M 94.2M 290M 225M 131M 86.6M 71.2M 68.4M
Intangible assets (CNY) — — 343,000 530,000 808,000 288,000 136,000 58,000 41,000
Right-of-use assets (CNY) — — — 0.00 12.7M 6.99M 1.73M 7.29M 6.12M
Net debt (borrowings + leases - cash) (CNY) — — -73.6M -289M -211M -124M — -468M -62.3M
Cash flow detail
Operating cash flow (CNY) — -149M -228M -11.3M -75M -66.2M -36M -12.6M -4.07M
Purchases of property, plant and equipment (CNY) — -23.2M -43M -9.24M -32.1M -8.99M -1.14M -742,000 -751,000
Purchases of intangible assets (CNY) — -147,000 -401,000 -608,000 -397,000 -27,000 -180,000 -76,000 0.00
Change in receivables (cash effect) (CNY) — 4.16M -65.9M -2M -2.97M -3.12M -1.75M -4.47M -4.43M
Change in inventories (cash effect) (CNY) — -32.3M -8.12M -1.45M -10.5M -3.14M 8.07M 344,000 357,000
Share buybacks (cash effect) (CNY) — 0.00 -3.64M 0.00 0.00 — — — —
Interest paid (cash effect) (CNY) — -13.8M -10.6M -544,000 -238,000 -127,000 0.00 0.00 -4,000
Income taxes paid (cash effect) (CNY) — — 0.00 0.00 -173,000 -14,000 0.00 0.00 0.00
Share-based compensation (CNY) — 5.1M 22.8M 26.5M 44.3M 47.4M 36.7M 21.3M 1.98M
Operating cash flow before change in receivables (CNY) — -153M -162M -9.27M -72M -63.1M -34.3M -8.17M 362,000
Free cash flow (OCF - PPE - intangibles) (CNY) — -172M -271M -21.1M -107M -75.3M -37.3M -13.5M -4.82M
Income detail
Research and development expense (CNY) — 105M 157M 40.5M 57.7M 61.2M 48.9M 31.8M 23.8M
↳ 5y CAGR -10.1%
Total comprehensive income (CNY) — -181M -145M -89.5M -131M -135M -91.5M -47M -8.5M
Comprehensive income to owners (CNY) — -181M -145M -89.5M -131M -135M -91.5M -47M -8.5M
Provision for credit losses (CNY) — 907,000 11.9M 2.09M 3.59M 3.75M -636,000 1.02M 1.91M
Credit cost ratio (credit losses / average receivables) (%) — — — 4.1% 25.7% 24.6% 3.8% 5.3% 8.5%
Reported Mar 23, 2021 Mar 23, 2021 Apr 29, 2022 Apr 29, 2022 Apr 29, 2024 Apr 29, 2024 Apr 29, 2024 Apr 28, 2026 Apr 28, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Annual General Meeting Bull 0 Bear 0 Routine

The Voting Instructions must be signed, completed and received at the indicated address

prior to 10:00 A.M. (New York City time) on December 15, 2026 for action to be taken.

ADS CUSIP No.: 12233L206.*

ADS Record Date: November 17, 2026.

Meeting Specifics: Annual General Meeting of Shareholders to be held on December 22, 2026 at 10:30 A.M. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai, and at any adjourned meeting thereof (the “Meeting”).

Meeting Agenda: Please refer to the Company’s Notice of Meeting enclosed herewith.

Depositary: Citibank, N.A.

Deposit Agreement: Deposit Agreement, dated as of June 16, 2020, as amended by Amendment No. 1 to Deposit Agreement, dated as of May 15, 2024.

Deposited Securities: Class A ordinary shares, par value US$0.0002 per share, of the Company.

Custodian: Citibank, N.A. - Hong Kong.

* ADR CUSIP No. is provided as a convenience only and without any liability for accuracy.

GUANGZHOU, China, November 17, 2026—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 22, 2026 at 10:30 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company’s website, within Investors Relation section, at https://ir.brbiotech.com.

The AGM will be held for the following proposals:

1. as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2026 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;

2. as an ordinary resolution, THAT Zhihong (Joe) Zhang and Wendy Hayes be re-elected as directors of the Company; and

3.

OverC® Multi-Cancer Detection Blood Test

—A Revolution in Multi-Cancer Early Detection

One tube of blood for precise early detection of 6 cancer types

Note: The FDA Breakthrough Device Designation for OverC applies to five cancer types: esophageal, lung, liver, pancreatic, and ovarian, and does not include colorectal cancer

Download Our Product Brochure Here Contact Us

Products

Solid Tumor Testing

Minimal Residual Disease Testing

Hematologic Malignancies Testing

RUO/IUO: Multi-omics Detection

Early Cancer Detection

Services

Pharma Biomarker & CDx Services

International Diagnostics Division

Sequencing Services

Early Cancer Detection Services

Resources

Publications

Events

Webinars

Documents

FAQs

Company

About Us

Press Release

Leadership Team

Core Technologies

Careers

Investor

Contact Us

US: 121 Innovation Drive Suite 100, Irvine CA, 92617

China: No.5, Xingdao Huanbei Road, International Bio Island, Guangzhou, Guangdong China 510300

Phone Number: China: 400-689-7600 US: (949)-732-6488

Email: [email protected]; [email protected]

© 2024 Burning Rock Dx | All rights reserved

Contact Our Experts

We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy , which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."

Reject All Accept All

Prompts

Burning Rock Biotech Limited (ticker BNR), listed in United States.

Company History

Date Change Detail
Dec 31, 2022 Reporting currency Its US reports are in USD instead of CNY from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.

ETFs Holding Burning Rock Biotech Limited

ETF Weight in ETF Shares Market value As of
BDVL short -0.11% -30,579 $ -1.957M Nov 16, 2026
IALT short -0.08% -95,463 $ -6.109M Nov 16, 2026
IDYN 0.02% 263 $ 16.829K Nov 16, 2026
CORO 0.02% 44,814 $ 2.868M Nov 16, 2026
ENHI 0.00% 1 $ 63.99 Nov 16, 2026